Dudediligence.

Celldex Therapeutics, Inc

CLDXNASDAQ · In Vitro & in Vivo Diagnostic Substances
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$3.2MSep ’24$1.2MDec ’24$695,000Mar ’25$730,000Jun ’25$121,000Dec ’25$15,000Mar ’26$22,000Jun ’26
Net income, by quarter
−$42.1MSep ’24−$47.1MDec ’24−$53.8MMar ’25−$56.6MJun ’25−$67.0MSep ’25−$81.3MDec ’25−$78.7MMar ’26−$73.5MJun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue$4.7M$2.4M$6.9M$7.0M$1.5M
Gross profit$4.6M$2.3M$6.6M$6.8M$1.3M
Operating income−$71.2M−$115.2M−$154.5M−$195.1M−$287.4M
Net incomenone on filenone on file−$141.4M−$157.9M−$258.8M
Operating cash flow−$60.9M−$103.7M−$107.3M−$157.8M−$210.9M
Free cash flow−$62.2M−$105.6M−$109.1M−$159.7M−$213.7M
Cash$39.1M$29.4M$34.8M$28.4M$28.9M
Shares outstanding46.7M47.2M55.9M66.4M66.5M